ArticleStem cells translational medicine2025
Potency of human hematopoietic cells from a novel CD34+ isolation technique.
Article in Stem cells translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hematopoietic stem and progenitor cells are responsible for maintenance of the immune system and can be a source of cells for therapies. A critical step in studying or utilizing hematopoietic cells is subpopulation isolation. FerroBio is an emerging technology that uses a streamlined, semi-automated approach to isolate CD34+ cells, which are highly enriched for hematopoietic stem and progenitors. This technology also results in isolation of bead-free CD34+ cell samples, in contrast to traditional kits where beads persist following isolation. Here, we showed a side-by-side comparison of FerroBio isolated cells with CD34+ cells isolated by traditional column-based kits. We showed that FerroBio yields similar numbers of CD34+ cells with similar viability, yield, and gated purity and higher overall purity compared to control kits. FerroBio isolated similar numbers of progenitor cells but significantly higher stem cells. Ex vivo, cells isolated by FerroBio showed the same ability to form colonies in culture, but FerroBio colony-forming units expanded to a greater extent in liquid culture compared to control. Critically, FerroBio isolated cells had equivalent long-term engraftment capacity with significantly better intermediate-term engraftment compared to control in mouse models of transplantation. Based on microscopy images showing altered morphology co-localized with beads, we inferred that the persistence of magnetic microbeads may be associated with the observed differences. These data demonstrated that specific subpopulations of progenitors from FerroBio isolated CD34+ cells have better potency compared to cells isolated with column-based kits. Thus, FerroBio is a viable strategy for isolating CD34+ cells for research and potentially translational utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.